PubMed Trending Research Digest — May 20, 2026

Automated digest · 96 articles · 15 research areas · May 20, 2026

Overview

Across this week’s PubMed highlights, a dominant theme is precision medicine that links measurable biology to actionable decisions. Several studies focus on biomarkers and risk stratification—ranging from circulating miRNA liquid biopsy for emerging anti-EGFR resistance in metastatic colorectal cancer, to multimodal AI systems for noninvasive breast cancer diagnosis, and to molecular/pathology frameworks that refine prognosis in cancers such as Wilms tumor and IDH-mutant gliomas. Complementing these, multiple works map disease states at high resolution (single-cell/spatial omics in tumor microenvironments, immune cell niches, and organ-specific pathology), aiming to identify which cellular programs drive progression, resistance, or poor outcomes.

A second major thread is mechanistic immunology and immunometabolism: how inflammatory signaling, immune cell dysfunction, and metabolic rewiring interact to determine disease trajectories. Examples include IL-6 as a causal mediator in acute lung injury/ARDS, checkpoint regulation layers that help explain limited ICI responses, and metabolic-immune axes such as kynurenic acid–GPR35 signaling in atrial fibrillation lymphatic dysfunction, DLD/malate pathways in metastasis under physical confinement, and macrophage/monocyte metabolic programs that shape neuroinflammation and liver disease progression. These mechanistic insights are increasingly paired with therapeutic strategies—topical JAK inhibition for prurigo nodularis, IL-33/ST2 and other cytokine-axis targeting in COPD, and multitarget biologics that combine lipid and inflammatory pathways.

Finally, the digest reflects rapid methodological and translational momentum. Multiple papers advance tools for discovery and measurement (multi-agent AI for hypothesis–experiment loops, accessible in vivo imaging platforms, and computational advances for spatial transcriptomics), while clinical studies emphasize scalable care delivery and real-world effectiveness (remote ICU rehabilitation, device-aided Parkinson’s therapy persistence, and evidence synthesis for CAR-T administration and acute PE mortality risk). Together, the set underscores a field moving toward tighter coupling of biology, computation, and clinical implementation.

---

Liquid biopsy & circulating biomarkers

Aptamer-Targeted PrPC Drives Colorectal Cancer Metastasis via a LYN-STAT3 Complex and Enables Liquid Biopsy Detection.

This study used Cell-SELEX to develop the colorectal cancer (CRC) aptamer probe WHY-3E and investigated its target PrP(C) in CRC tissues and models. The authors found that PrP(C) is upregulated in CRC and promotes metastasis through a LYN–STAT3 signaling complex, enabling liquid-biopsy detection using the aptamer. These findings position PrP(C) as a metastasis-driving biomarker and WHY-3E as a potential platform for noninvasive CRC diagnosis and monitoring.

Wang C, Wu H, Zheng C et al. · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · (2026) · View on PubMed ↗ · Free PDF ↗

EXONERATE-TRaCE: A Liquid Biopsy for Tracking Response to Anti-Epidermal Growth Factor Receptor-Based Therapy in Metastatic Colorectal Cancer.

The EXONERATE-TRaCE study evaluated the EXOsome/cell-free microRNA liquid biopsy assay (EXONERATE) for monitoring emergence of anti-EGFR resistance during treatment in patients with metastatic colorectal cancer receiving anti-EGFR monoclonal antibody therapy. Longitudinal assay performance was assessed to predict response and detect resistance before it becomes clinically or radiologically evident. This provides a clinically actionable framework for dynamic, noninvasive tracking of anti-EGFR efficacy and resistance in mCRC using circulating miRNA signatures.

Takahashi T, Mannucci A, Shigeyasu K et al. · JCO precision oncology · (2026) · View on PubMed ↗

---

Precision oncology biomarkers & risk stratification

A deep learning system for non-invasive breast cancer diagnosis with multimodal data.

This study developed and evaluated BINDS, a deep learning system for non-invasive breast cancer diagnosis that integrates multimodal imaging data (ultrasound and/or mammography followed by magnetic resonance imaging) for risk assessment and subtype classification. BINDS uses a two-stage diagnostic workflow aligned to clinical practice to improve breast cancer detection without relying on immediate biopsy. Scientifically and clinically, it provides an AI framework for multimodal, workflow-matched, non-invasive breast cancer stratification.

Li Y, Zhang J, Chen H et al. · Nature biomedical engineering · (2026) · View on PubMed ↗

Chromatin context-dependent deacetylation by the asymmetric Rpd3L.

This structural biology study investigated how the asymmetric Rpd3L (a Sin3 HDAC complex) deacetylates chromatin in a context-dependent manner. Using cryo-electron microscopy with mono- and di-nucleosome substrates, the authors found a substrate-guided allosteric activation mechanism in which Rpd3L adopts an asymmetric architecture that enables catalytic activation depending on nucleosome context. The work provides a mechanistic framework for how HDAC complexes achieve specificity on chromatin, informing epigenetic drug design targeting deacetylation pathways.

Zhao H, Li H, Wang C et al. · Nucleic acids research · (2026) · View on PubMed ↗ · Free PDF ↗

cIMPACT-NOW update 12: Refining Pathology-based Risk Stratification and Grading for IDH-mutant Gliomas.

A cIMPACT-NOW working group reviewed pathology literature to refine CNS WHO grade 2–3 risk stratification for IDH-mutant gliomas and to incorporate newly described molecular subgroups. PDGFRA amplification in IDH-mutant astrocytomas was associated with highly aggressive clinical behavior consistent with CNS WHO grade 4, while alterations such as PIK3 mutations and EGFR (as reported in the abstract) aligned with intermediate risk and most consistently with CNS WHO grade 3. These pathology–molecular links are intended to improve risk-based grading and treatment decisions for patients with IDH-mutant gliomas at the grade 2/3 interface.

Brat DJ, Aldape K, French PJ et al. · Neuro-oncology · (2026) · View on PubMed ↗

ATP1A3-related syndromes: our case-series unveiling a dynamic, fever-triggered and overlapping array of neurological phenotypes.

This case series studied ATP1A3-related neurological disorders in patients presenting with fever-triggered and overlapping phenotypes across the ATP1A3 spectrum. The key finding was that fever can precipitate dynamic clinical presentations that overlap known ATP1A3 syndromes (including conditions such as AHC/RDP/CAPOS-like features and related rarer entities). Scientifically, it emphasizes the need to consider ATP1A3 in fever-induced, multi-phenotype neurological presentations and to refine genotype–phenotype understanding for autosomal dominant ATP1A3 disorders.

Errichiello G, Bernardo P, Acquaviva F et al. · Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · (2026) · View on PubMed ↗ · Free PDF ↗

H3K27me3 spreading organizes canonical PRC1 chromatin architecture to regulate developmental programs.

This study investigated how spreading of the Polycomb mark H3K27me3 organizes canonical PRC1 (cPRC1) chromatin architecture to regulate developmental gene silencing and cell fate specification, using glioma-derived H3K27M mutations to restrict H3K27me3 spreading. Confining H3K27me3 increased the cPRC1 chromatin pool and enhanced 3D interactions that recapitulated altered Polycomb looping patterns affecting target gene silencing. These results clarify a mechanistic link between H3K27me3 spreading, PRC1 genome architecture, and developmental program control, with implications for Polycomb dysregulation in cancer.

Krug B, Hu B, Chen H et al. · Nature genetics · (2026) · View on PubMed ↗

Integrated biomarker and treatment correlates of prognosis in infant non-WNT/non-SHH medulloblastoma: a multinational retrospective cohort study.

This multinational retrospective cohort study analyzed infant non-WNT/non-SHH medulloblastoma (age <3–5 years at diagnosis) to determine whether clinicomolecular features and integrated biomarkers can stratify prognosis and relate to outcomes across different therapeutic approaches. The key finding is that non-WNT/non-SHH infant medulloblastoma—previously treated as uniformly high risk—can be biologically subclassified with prognostic and treatment-correlate differences. This is scientifically and clinically significant because it supports risk-adapted stratification and more rational selection of therapy for this high-need paediatric subgroup.

Richardson S, Hicks D, Gough M et al. · The Lancet. Child & adolescent health · (2026) · 1 citations · View on PubMed ↗ · Free PDF ↗

Use of ALK Inhibitors in Patients With Nonlung Malignancies Bearing ALK Alteration Prolongs Treatment Duration.

This JCO Precision Oncology descriptive analysis studied patients with nonlung malignancies harboring ALK alterations who received ALK inhibitors outside of FDA-approved indications, excluding NSCLC, ALCL, and inflammatory myofibroblastic tumors and excluding trial-treated patients. The key finding is that ALK inhibitor use in these nonlung ALK-altered cancers was associated with prolonged treatment duration compared with expectations from limited prior data. This is clinically significant because it supports broader real-world effectiveness and informs treatment planning for ALK-driven tumors lacking formal approval.

Abreu de Góes V, Lee M, Zugman M et al. · JCO precision oncology · (2026) · View on PubMed ↗

Systematic Review: Prognostic Molecular Biomarkers in Wilms Tumors.

This systematic review assessed prognostic molecular biomarkers in children with Wilms tumor, focusing on genomic copy-number alterations (including 1q gain and 1p loss) and other candidate markers reported in de novo Wilms tumors. Across eligible studies (≥50 tumors) up to January 2025, it synthesized evidence for which biomarkers are associated with outcomes and therefore could support risk stratification in Children’s Oncology Group and SIOP-RENAL/UMBRELLA contexts. The work is significant for guiding selection and validation of molecular markers to enable more precise, risk-adapted therapy planning in pediatric Wilms tumor.

Oller A, Kemmeren P, Perotti D et al. · JCO precision oncology · (2026) · View on PubMed ↗ · Free PDF ↗

---

Cancer therapeutics: antibodies, ADCs, and targeted biologics

Targeting ANGPTL3 and IL-33/ST2 Ameliorates Diabetic Kidney Disease by Reducing Lipotoxicity, Alleviating Inflammation and Inhibiting Fibrosis.

This preclinical study engineered a bifunctional fusion protein (FD03-sST2) combining an anti-ANGPTL3 nanobody with an IL-33 decoy to test whether dual targeting ameliorates diabetic kidney disease (DKD). In DKD models, inhibiting ANGPTL3 and IL-33 reduced renal lipotoxicity, inflammation, and fibrosis, thereby improving kidney injury outcomes. The work supports a multitarget biologic strategy that links lipid metabolism and the IL-33/ST2 inflammatory-fibrotic axis as a therapeutic approach for DKD.

Li Z, Cao Z, Zhou R et al. · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · (2026) · View on PubMed ↗ · Free PDF ↗

DDX5 (p68) and UbE2T as emerging superior cancer therapeutic targets: dual molecular glue target degradation by FL118 for conquering difficult-to-treat cancers.

This review examined DDX5 (p68) and UbE2T as cancer therapeutic targets and focused on dual molecular glue target degradation using the small-molecule degrader FL118 in difficult-to-treat advanced solid cancers. The key finding is that FL118 can simultaneously degrade DDX5 and UbE2T, with downstream consequences tied to DNA repair pathway dependencies. This provides a mechanistic rationale for exploiting dual molecular glue degradation to overcome resistance in cancers reliant on DDX5/Ube2T-mediated repair.

Li F, Ling X, Chakraborty S et al. · Journal of experimental & clinical cancer research : CR · (2026) · View on PubMed ↗ · Free PDF ↗

Antibody-Drug Conjugates in Non-small Cell Lung Cancer.

This review studied the design and clinical development of antibody-drug conjugates (ADCs) in patients with previously treated advanced non-small cell lung cancer (NSCLC), spanning oncogene-addicted and non-oncogene-addicted tumors. It found that ADCs can selectively deliver cytotoxic payloads to tumor cells via antigen binding, internalization, linker degradation, and intracellular payload release, with ongoing phase II/III trials addressing resistance to standard therapies. These findings are significant because they support ADCs as an expanding targeted strategy for improving outcomes in refractory NSCLC beyond conventional chemotherapy and targeted kinase inhibition.

Zullo L, Bortolot M, Ogliari FR et al. · Drugs · (2026) · View on PubMed ↗ · Free PDF ↗

Durvalumab plus HAIC-FOLFOX followed by maintenance durvalumab for hepatocellular carcinoma with major portal invasion: phase 2 DurHope study.

This phase 2 DurHope study evaluated durvalumab combined with hepatic arterial infusion chemotherapy (HAIC) using the FOLFOX regimen (fluorouracil, leucovorin, oxaliplatin) followed by maintenance durvalumab in 30 hepatocellular carcinoma patients with major portal invasion (Vp3/4 portal vein tumor thrombus). The trial reported a 1-year overall survival (OS) rate of 63.3% with prespecified endpoints achieved, along with safety and efficacy outcomes including progression-free survival and objective response rate. These clinical results support durvalumab plus HAIC-FOLFOX as a potential first-line option for high-risk HCC patients with major portal invasion who are underrepresented in many trials.

Yi J, Wang J, Zhang Y et al. · Nature communications · (2026) · View on PubMed ↗ · Free PDF ↗

Docetaxel plus ramucirumab immediately after immunotherapy in advanced NSCLC: A phase II study (DRUN).

This multicenter, single-arm phase II study (DRUN) evaluated docetaxel plus ramucirumab given immediately after progression on an immune checkpoint inhibitor–containing regimen in patients with advanced non-small cell lung cancer (NSCLC). The key finding is the trial’s objective response rate (ORR) and associated efficacy outcomes (including progression-free survival and overall survival) for this post-immunotherapy sequencing strategy. This is clinically significant because it provides prospective evidence on whether standard second-line docetaxel/ramucirumab remains effective after prior ICI therapy.

Harutani Y, Akamatsu H, Sugimoto T et al. · Lung cancer (Amsterdam, Netherlands) · (2026) · View on PubMed ↗ · Free PDF ↗

Survival Analysis of the WSG TP-II Trial: Neoadjuvant Trastuzumab and Pertuzumab Plus Endocrine Therapy Versus Chemotherapy in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.

The WSG TP-II trial survival analysis studied 12 weeks of neoadjuvant trastuzumab plus pertuzumab combined with endocrine therapy versus weekly paclitaxel plus trastuzumab plus pertuzumab in patients with hormone receptor-positive/HER2-positive early breast cancer. The final 5-year analysis extended the earlier finding that the paclitaxel-containing arm achieved a higher pathologic complete response rate (56.4% vs 23.7%). This is clinically important because it supports optimizing neoadjuvant regimens to improve long-term outcomes in HR+/HER2+ early breast cancer.

Gluz O, Nitz UA, Christgen M et al. · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · (2026) · View on PubMed ↗

Injectable Binary-Amplified Cascade Hydrogels Suppress Post-Incomplete Microwave Ablation Relapse via Integrated Metallo-Metabolic-Immunomodulation.

This ACS Nano study developed an injectable binary-amplified cascade hydrogel (S/CuCo@HD) delivering the CD36 inhibitor sulfosuccinimidyl oleate (SSO) and a copper-cobalt bimetal-organic framework (Cu-Co BMF) to suppress relapse after incomplete microwave ablation (iMWA) in hepatocellular carcinoma. The hydrogel was designed to provide sustained local release in tumor cavities and to integrate metallo-metabolic-immunomodulation to overcome residual tumor cell death resistance and the myeloid immunosuppressive microenvironment. The approach is significant as a translational strategy to reduce post-ablation recurrence by combining targeted metabolic inhibition (via CD36 blockade) with local immunomodulatory biomaterials.

Liu Y, Qin J, Fang K et al. · ACS nano · (2026) · View on PubMed ↗ · Free PDF ↗

---

Cell therapy (CAR-T and other cellular immunotherapies)

Consensus Recommendations for CAR T-Cell Administration in Adult Acute Lymphoblastic Leukemia: a Modified Delphi Study.

This modified Delphi study investigated expert consensus on best practices for administering commercially available CD19 CAR T-cell therapies in adults with B-cell acute lymphoblastic leukemia (B-ALL). A panel of 9 principal investigators developed and validated consensus recommendations addressing key clinical questions for CAR T-cell administration in this population. The clinical significance is standardized guidance to improve real-world delivery and decision-making for adult CD19 CAR T therapy where randomized evidence is limited.

Muffly L, Frey NV, Roloff GW et al. · Blood · (2026) · View on PubMed ↗

Challenges and advances in CAR-T cell therapy for B-ALL.

This review summarized current evidence on CAR-T cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), focusing on clinical limitations and mitigation strategies. The key finding is that despite high initial response rates, relapse driven by antigen escape and limited CAR-T persistence, plus toxicities such as cytokine release syndrome and immune effector cell-associated neurotoxicity, remain major barriers. Addressing these issues is clinically significant for improving durability, safety, and access of CAR-T therapies in B-ALL.

Zha C, Wang Y · Biomarker research · (2026) · View on PubMed ↗ · Free PDF ↗

Chimeric antigen receptor T-cell (CAR-T) therapy and other cellular immunotherapy treatments for idiopathic inflammatory myopathies.

This review evaluated evidence for chimeric antigen receptor T-cell (CAR-T) therapy and other cellular immunotherapies in idiopathic inflammatory myopathies (IIM), including immune-mediated necrotizing myopathy, dermatomyositis, anti-synthetase syndrome, overlap myositis, and polymyositis. It highlights that autoreactive B cells and autoantibody-producing plasma cells are central drivers in multiple IIM subtypes, providing a rationale for B-cell–targeted cellular therapies. The review is significant for guiding future clinical development and trial design of cellular immunotherapies for steroid-refractory or persistent IIM.

Paul JR, Gandiga PC, Aggarwal R · Best practice & research. Clinical rheumatology · (2026) · View on PubMed ↗

Condensed vs. Standard Step-Up Dosing Schedule of Talquetamab in Relapsed/Refractory Multiple Myeloma.

This multicenter retrospective study compared condensed versus standard step-up dosing schedules of talquetamab in relapsed/refractory multiple myeloma, evaluating incidence and severity of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Patients receiving the condensed step-up schedule (Days 1, 3, 5, 7) were compared with those receiving the standard schedule (Days 1, 4, 7, 10) across seven US academic centers. The findings are clinically important because they assess whether a faster step-up regimen can maintain safety while improving treatment practicality.

Elsey G, Davis JA, Julian K et al. · European journal of haematology · (2026) · View on PubMed ↗

Total marrow and lymphoid irradiation in combination with cyclophosphamide and etoposide before haematopoietic cell transplantation for relapsed or refractory acute leukaemia: a single-centre, open-label, phase 2 trial.

This single-centre, open-label phase 2 trial studied total marrow and lymphoid irradiation (2000 cGy to bone marrow and lymph nodes) combined with high-dose cyclophosphamide and etoposide as conditioning before allogeneic haematopoietic cell transplantation in patients aged 16–60 years with relapsed or refractory acute leukaemia. The key finding reported in the abstract is the trial’s assessment of effectiveness and safety of this combined conditioning approach, following an initial six-patient safety lead-in. If effective, this regimen could improve transplant outcomes in relapsed/refractory acute leukaemia by optimizing radiation plus chemotherapy conditioning while maintaining acceptable toxicity.

Stein A, Wang Y, Malki MMA et al. · The Lancet. Haematology · (2026) · View on PubMed ↗

---

Immunotherapy mechanisms & immune evasion

The immunology of human breast cancer.

This review studied the immunology of human breast cancer in the context of immune checkpoint inhibitor (ICI) therapy across breast cancer subtypes. The key finding was that while some tumors have a baseline immunological configuration that can be targeted for durable responses, most breast cancers—especially non-triple-negative disease—show poor ICI responsiveness due to tumor-intrinsic and microenvironmental immunosuppressive barriers. This is significant because it frames why immunotherapy success is limited in many breast cancer patients and highlights targets for overcoming resistance beyond current ICI strategies.

García-Torralba E, Loi S, Salgado R et al. · Nature reviews. Immunology · (2026) · View on PubMed ↗

Autophagy modulation in cancer.

This review summarized how autophagy is regulated and how it can either suppress or support cancer depending on context, focusing on lysosome-dependent cellular quality control and nutrient-stress responses. It highlights that autophagy defects can favor malignant transformation, while proficient autophagy often helps tumors survive harsh microenvironments and can influence therapeutic responses. The synthesis underscores autophagy modulation as a drug-development opportunity but emphasizes the need for context-specific strategies in cancer therapy.

Guilbaud E, Ryan KM, Green DR et al. · Nature reviews. Drug discovery · (2026) · View on PubMed ↗

Regulation of immune checkpoint molecules in cancer immune evasion and therapy.

This review examined multilayered regulation of immune checkpoint molecules involved in cancer immune evasion and therapy, emphasizing clinically validated axes such as PD-L1/PD-1 and CTLA4 and the LAG3 axis. It found that limited or transient responses to immune checkpoint inhibitors are frequently linked to dysregulation of checkpoint expression and control mechanisms across genetic, epigenetic, transcriptional, and post-transcriptional layers. The article frames checkpoint regulation as a key determinant of resistance and a rationale for next-generation combination or biomarker-guided immunotherapies.

Eris C, Zu C, Xiao Y et al. · Nature reviews. Cancer · (2026) · View on PubMed ↗

DNA-PK-mediated CRTC2 phosphorylation promotes NHEJ and suppresses antitumor immunity via relocation to repair complexes.

This work investigated how DNA-PKcs signaling regulates the transcriptional coactivator CRTC2 during genotoxic stress in cancer-relevant cellular and in vivo models. DNA-PK-mediated phosphorylation of CRTC2 at Ser433 promotes NHEJ by enabling PARP1-dependent recruitment of CRTC2 to DNA breaks and DNA-PK holoenzyme assembly, while also suppressing antitumor immunity by dissociating CRTC2 from transcriptional complexes. These findings link DNA-PK–CRTC2 post-translational control to repair pathway choice and immune evasion, suggesting CRTC2 Ser433 as a potential therapeutic intervention point.

Zou F, Yao Z, Dong X et al. · Nature communications · (2026) · View on PubMed ↗ · Free PDF ↗

TRIM28-mediated SUMOylation of SREBF1 drives PD‑L1 N‑glycosylation and immune evasion in bladder cancer.

This study examined how TRIM28-mediated SUMOylation regulates SREBF1 to drive PD‑L1 N-glycosylation and immune evasion in bladder cancer. TRIM28 interacted with SREBF1 and catalyzed SUMO2 conjugation at K470, stabilizing SREBF1 and increasing its occupancy at relevant targets to promote PD‑L1 N-glycosylation and tumor immune escape. These findings connect a specific SUMO site on SREBF1 to PD‑L1 glycosylation control, identifying a mechanistic axis that could be exploited to counter immune evasion in bladder cancer.

Chen R, Su Y, Chen J et al. · Cell death & disease · (2026) · View on PubMed ↗ · Free PDF ↗

Interleukin-6 is a mediator of therapeutic efficacy in acute lung injury.

This study used individual patient data from five large randomized controlled trials to test whether interleukin-6 (IL-6) mediates the therapeutic efficacy of interventions in acute lung injury, including ARDS and COVID-19. By leveraging causal mediation approaches on pooled trial data, it assessed IL-6 as a mechanistic link between treatment and clinical outcomes. Establishing IL-6 as a mediator is scientifically and clinically important because it can refine understanding of treatment pathways and support biomarker-guided targeting of IL-6–driven inflammation.

Kramer L, Calfee CS, Mcauley DF et al. · American journal of respiratory and critical care medicine · (2026) · View on PubMed ↗ · Free PDF ↗

---

Tumor microenvironment & spatial/omics mapping

Senescent-like neutrophils shape angiogenic immunosuppressive niches in colorectal cancer liver metastasis.

This study characterized tumor-associated neutrophils in colorectal cancer liver metastasis (CRLM) using single-cell RNA sequencing and Stereo-seq spatial-enhanced-resolution-omics-sequencing. It identified a terminally differentiated pro-tumor neutrophil subset (TAN1) with a glycolysis signature and senescent phenotype that was enriched in liver metastases and associated with poor prognosis, and it implicated BHLHE40 upregulation in TAN1 differentiation from other TAN subsets. The work is significant because it links a specific senescent-like neutrophil state to metastatic immunosuppressive niches and prognosis, suggesting potential targets for therapy.

Chen Z, Ren X, Zhang Y et al. · Cancer discovery · (2026) · View on PubMed ↗

Molecular insight into the interplay among heterogeneous plasmacytes and microenvironment cells and their clinical relevance in myeloma.

This study investigated the interplay between heterogeneous plasmacytes and microenvironment cells in multiple myeloma (MM) and its clinical relevance using data from the Shanghai MM Omics (SMMO) project. In 277 newly diagnosed MM patients (with whole-genome/whole-exome sequencing and RNA-seq) and single-cell RNA-seq from 59 patients plus additional relapsed and normal controls, the authors defined three genetic groups (MY, HRD, and MS/CD) and mapped plasmacyte–microenvironment heterogeneity across disease states. Clinically, the results provide a framework for connecting genomic subtypes to microenvironment-driven biology that may inform prognosis and personalized treatment strategies in Chinese MM cohorts.

Jiang L, Liu CL, Zhang YL et al. · Proceedings of the National Academy of Sciences of the United States of America · (2026) · View on PubMed ↗

ASCL2-mediated macrophage-myofibroblast transition generates immunosuppressive CAF_7 in NSCLC bone metastases.

This study investigated whether tumor-associated macrophages undergo macrophage-to-myofibroblast transition (MMT) to generate an immunosuppressive cancer-associated fibroblast (CAF) subset in NSCLC bone metastases, driven by the transcription factor ASCL2. Using integrated single-cell RNA sequencing of primary lung tumors and bone metastases with pseudotime/regulon analyses (and additional validation assays), the authors identified an ASCL2-mediated pathway producing CAF_7 that supports immune suppression in bone lesions. This mechanistic insight is significant because it links a specific TAM→MMT→CAF program to immunotherapy resistance in NSCLC bone metastasis.

Wang J, Qian J, Yang X et al. · Journal of experimental & clinical cancer research : CR · (2026) · View on PubMed ↗ · Free PDF ↗

DKC1 promotes colorectal cancer progression and therapy resistance by dysregulating sphingolipid biosynthesis.

This study examined the role of DKC1 in colorectal cancer progression and therapy resistance, integrating transcriptomic/lipidomic analyses with functional assays in CRC models. DKC1 promoted cell-cycle progression, apoptosis suppression, stemness, and drug resistance through a WNT signaling feedback loop and dysregulated sphingolipid biosynthesis, correlating with poor prognosis and WNT-enriched CMS2 signatures. The results position DKC1–sphingolipid pathway remodeling as a mechanistic driver of CRC aggressiveness and a candidate target to overcome treatment resistance.

Khan UK, Goel A, Nigam S et al. · Nature communications · (2026) · View on PubMed ↗ · Free PDF ↗

---

Metabolism, inflammation, and immunometabolism in disease

Precision nutrition for the prevention and management of inflammatory bowel disease.

This Review examined how precision nutrition—tailored dietary recommendations using multidimensional individual characteristics including demographics, disease natural history, and multiomics traits—could prevent and manage inflammatory bowel disease (IBD). It highlights key sources of heterogeneity in dietary responses and proposes a stepwise framework starting with phenotype-based precision nutrition. Clinically, this supports moving beyond one-size-fits-all diets toward mechanism- and phenotype-informed nutrition strategies to improve IBD outcomes.

Chen J, Dan L, Wellens J et al. · Nature reviews. Gastroenterology & hepatology · (2026) · View on PubMed ↗

FGF10 mitigated sepsis-induced pulmonary coagulopathy via Nrf2/PINK1/Parkin-modulated mitophagy.

This study tested whether recombinant human FGF10 (rFGF10) mitigates sepsis-induced pulmonary coagulopathy in mice and in LPS-stimulated human umbilical vein endothelial cells (HUVECs). rFGF10 reduced coagulation factor dysregulation and endothelial dysfunction and mechanistically promoted Nrf2/PINK1/Parkin-modulated mitophagy. These results suggest FGF10 as a potential host-directed therapy to prevent microvascular coagulation complications in sepsis.

Wu M, Wang H, Huang Y et al. · American journal of respiratory cell and molecular biology · (2026) · View on PubMed ↗

Organelle contact reorganization drives calcium-dependent autophagy under proteostatic stress.

This study examined how proteostatic stress and VCP/p97 inhibition trigger calcium-dependent autophagy through reorganization of organelle contact sites, using human endothelial cells (HUVECs) and mechanistic cellular assays. The key finding is that allosteric VCP inhibition induces cell-type–specific macroautophagy/autophagy by dynamically remodeling inter-organelle contact sites in a calcium-dependent manner. Scientifically, it clarifies why VCP inhibitors can create selective vulnerability and suggests combination strategies that modulate calcium signaling or autophagy pathways.

Ko YB, Ko M, Ueffing M et al. · Autophagy · (2026) · View on PubMed ↗

Cutaneous Manifestations in Psoriatic Arthritis: Phenotypes, Clinical Burden, and Therapeutic Implications.

This review studied cutaneous manifestations in patients with psoriatic arthritis (PsA), focusing on clinical phenotypes (nail, scalp, palmoplantar, and inverse involvement) and their impact on disease burden and treatment response. The key finding was that these cutaneous phenotypes are relatively common in PsA and are often associated with greater functional limitation, worse quality of life, and discordant responses to systemic therapy. Clinically, it underscores the importance of phenotype-specific skin assessment for diagnosis, risk stratification, and optimizing systemic treatment selection in PsA.

Tsafis K, Skepastianos V, Skouvaklidou E et al. · Rheumatology and therapy · (2026) · View on PubMed ↗ · Free PDF ↗

Compression-induced metabolic adaptation drives confined tumor cell migration and distant metastasis via malate-dependent microtubule reinforcement.

This mechanistic study used a CRISPR screen targeting 1685 metabolic enzymes to investigate how confined tumor cell migration promotes distant metastasis, focusing on the metabolic enzyme dihydrolipoamide dehydrogenase (DLD). The key finding was that compression-induced metabolic adaptation drives confined migration and metastasis through malate-dependent microtubule reinforcement, linking a specific metabolic pathway to physical-environment-driven metastatic behavior. Scientifically, it identifies DLD/malate–microtubule signaling as a potential vulnerability for limiting metastasis in tumors that must traverse dense or narrow anatomical spaces.

Liu M, Liu B, Chen C et al. · Cell research · (2026) · View on PubMed ↗

Monocyte infiltration induces CNS arginine catabolism to fuel neuroinflammation.

This study examined how monocyte-derived cells (Mdcs) infiltrating the CNS reprogram tissue metabolism during mouse neuroinflammation, using genetic fate mapping, metabolomics, and metabolite imaging. CNS Mdc infiltration increased lesion-associated arginase 1 (Arg1)-driven arginine catabolism, promoting oxidative damage, lipid accumulation, and Mdc dysfunction. These findings identify Arg1-mediated arginine metabolism as a mechanistic metabolic driver of neuroinflammation and a potential therapeutic target to limit harmful Mdc activity in CNS disease.

Kerndl M, Musiejovsky L, Komljenovic A et al. · Nature immunology · (2026) · View on PubMed ↗ · Free PDF ↗

Integrated multi-omics identifies distinct macrophage alterations during progression of metabolic dysfunction-associated steatohepatitis.

This study profiled hepatic macrophage changes across the MASLD spectrum (steatosis to metabolic dysfunction-associated steatohepatitis, MASH) in human samples using single-nucleus transcriptomics, spatial multi-omics, and proteomics. It found progressive Kupffer cell depletion alongside emergence of multiple phenotypically distinct macrophage subsets as disease advanced toward MASH. The work provides a dynamic, spatially resolved macrophage atlas that can guide biomarker discovery and macrophage-targeted interventions for MASLD/MASH progression.

Boesch M, Anak S, El Abyad D et al. · Nature genetics · (2026) · View on PubMed ↗ · Free PDF ↗

Cardiolipin preserves Treg metabolic fitness and immune homeostasis in the gut.

This study tested how cardiolipin supports regulatory T (Treg) cell metabolic fitness and gut immune homeostasis in mice, focusing on the cardiolipin-synthesizing enzyme protein tyrosine phosphatase mitochondrial 1 (PTPMT1). Deleting PTPMT1 in T cells predisposed mice to colitis by impairing Treg function, and subsequent pathobiont infections accelerated inflammation severity. Mechanistically, cardiolipin loss disrupted Treg metabolic programs, identifying a host lipid pathway that can modulate Treg stability and inflammatory bowel disease risk.

Regina A, Solagna F, Estrada MS et al. · Nature metabolism · (2026) · View on PubMed ↗ · Free PDF ↗

Advanced nanoformulations of NUAK1 regulate NLRP3 inflammasome for preeclampsia management in mice.

This study evaluated folic acid-modified lipid nanoparticles co-loaded with polydopamine and NUAK Family Kinase 1 (NUAK1), FLN@(PDA+NUAK1) NPs, for preeclampsia therapy in an L-NAME-induced mouse model and in oxidative-stress cell assays. The nanoformulation reduced reactive oxygen species, suppressed NLRP3 inflammasome activation, promoted autophagy, and inhibited apoptosis under oxidative stress. This supports NUAK1 delivery as a targeted anti-inflammatory/anti-oxidative strategy for managing preeclampsia by modulating NLRP3-driven pathology.

Jiang P, Ying X, Li Z et al. · Nature communications · (2026) · View on PubMed ↗ · Free PDF ↗

Myeloid Mas drives pyruvate kinase M2-mediated Spi1 lactylation to fuel inflammatory senescence in MASLD.

This study investigated how myeloid-expressed Mas (a G protein-coupled receptor) regulates pyruvate kinase M2 (PKM2)-mediated Spi1 lactylation and inflammatory senescence in metabolic dysfunction-associated steatotic liver disease (MASLD) using human hepatic myeloid cells and diet-induced mouse models with myeloid-specific Mas1 deletion. Myeloid Mas1 deletion attenuated MASLD by restraining glycolytic reprogramming and inflammatory senescence, and single-cell RNA sequencing showed impaired glycolytic flux and pathogenic differentiation of FN1+CCR2+ monocyte precursors. These findings identify the Mas–PKM2–Spi1 lactylation axis as a mechanistic immune-metabolism checkpoint and a potential therapeutic target to limit MASLD progression.

Zhao L, Xu S, Qiao S et al. · Signal transduction and targeted therapy · (2026) · View on PubMed ↗ · Free PDF ↗

The Hippo Pathway in Intestinal Regeneration, Fetal Reprogramming, and Tumorigenesis.

This perspective article reviewed the Hippo signaling pathway’s roles in intestinal regeneration, fetal reprogramming, and tumorigenesis, focusing on MST1/2 and LATS1/2 regulation of YAP/TAZ activity. It emphasizes that YAP/TAZ is normally repressed in the intestine to maintain homeostasis but becomes transiently activated after injury to promote regeneration, while dysregulated Hippo-YAP signaling can contribute to tumorigenesis. The synthesis is scientifically significant because it connects pathway control of proliferation/survival to tissue repair and cancer risk, informing therapeutic strategies targeting Hippo-YAP signaling.

Man V, Wrana JL · Cold Spring Harbor perspectives in biology · (2026) · View on PubMed ↗

Soft substrate priming erases fibrotic mechanical memory in mesenchymal stromal cells via YAP lysosomal degradation to improve therapeutic efficacy for spinal cord injury.

This Biomaterials study investigated how fibrotic mechanical memory in mesenchymal stromal cells (MSCs) affects therapeutic efficacy for spinal cord injury (SCI), focusing on mechanotransduction pathways involving YAP and lysosomal degradation. The key finding is that soft substrate priming erases fibrotic mechanical memory in MSCs via YAP lysosomal degradation (and a YAP/Smad-dependent stiffening mechanism), improving their therapeutic performance in SCI. This is significant because it provides a mechanobiology-based preconditioning approach to overcome the chronic-phase loss of MSC efficacy in a stiff, fibrotic scar environment.

Yao S, Lv Y, Pang M et al. · Biomaterials · (2026) · View on PubMed ↗

---

Microbiome & host-microbe metabolic signaling

Limosilactobacillus reuteri promotes melatonin release from human intestinal organoids via 5’ectonucleotidase activity.

This study tested whether Limosilactobacillus reuteri promotes melatonin release from human intestinal organoids and identified the mechanism as 5’ectonucleotidase (5’NT) activity. The key finding is that L. reuteri DSM 17938 increases melatonin release in organoid models via extracellular AMP breakdown by 5’NT, leading to adenosine-mediated signaling that stimulates melatonin production. Clinically, it supports a gut-microbe–to–melatonin pathway that could explain therapeutic effects of specific L. reuteri strains and guide microbiome-based interventions.

Forshee MD, Nachman EJ, Shenoy ER et al. · Gut microbes · (2026) · View on PubMed ↗ · Free PDF ↗

Inorganic nitrogen metabolic reprogramming of the gut microbiome drives fecal microbiota transplantation in ulcerative colitis.

This study investigated how inorganic nitrogen metabolic reprogramming of the gut microbiome influences fecal microbiota transplantation (FMT) engraftment outcomes in ulcerative colitis using an LD50-based ecological model. It found that inorganic nitrogen utilization capacity (IN-uc) governs microbial assembly under high oxidative stress and strongly affects donor engraftment, and it engineered a probiotic-metabolite consortium (PM-mix14) to increase IN-uc and reduce oxidative-stress colonization barriers. The work provides a mechanistic lever to improve FMT success in UC by targeting nitrogen metabolism to enhance donor microbiota establishment.

Wang Y, Hou Q, Lv X et al. · Nature communications · (2026) · View on PubMed ↗ · Free PDF ↗

Gut microbiota-induced perturbation in bile acids alter keratinocyte lipid metabolism via FXR-NQO1 signaling in psoriasis.

This study investigated how gut microbiota–driven bile acid perturbations affect keratinocyte lipid metabolism in psoriasis, combining analyses of psoriasis patients with imiquimod-treated female mice. It found increased keratinocyte farnesoid X receptor (FXR) expression and showed that FXR activation by glycochenodeoxycholic acid (GCDCA) ameliorated psoriatic symptoms by enhancing fatty acid oxidation and lipid metabolism. Mechanistically, FXR improved antioxidant capacity by upregulating NQO1, linking bile acid–FXR–NQO1 signaling to oxidative stress control in psoriasis.

Lian P, Lu R, Gu C et al. · Nature communications · (2026) · View on PubMed ↗ · Free PDF ↗

---

Cardiovascular disease: risk, prevention, and mechanistic cardiology

Kynurenic acid mediates epicardial fat-induced lymphatic metabolic dysfunction in atrial fibrillation.

This work investigated how kynurenic acid links epicardial fat to atrial lymphatic dysfunction in atrial fibrillation, using human left atrial appendage specimens and mechanistic experiments in models of atrial lymphangiogenesis. The authors found reduced lymphatic vessel density in atrial fibrillation versus sinus rhythm and showed that epicardial adipose tissue from atrial fibrillation patients secretes kynurenic acid, which acts via the receptor GPR35 to disrupt lymphatic endothelial mitochondrial homeostasis and promote endothelial-to-mesenchymal transition. These findings identify a kynurenic acid–GPR35 axis as a mechanistic driver of impaired atrial lymphangiogenesis and a potential therapeutic target in atrial fibrillation.

Takahashi M, Abe I, Yoshida N et al. · Nature communications · (2026) · View on PubMed ↗

Evolocumab in Patients With Prior Percutaneous Coronary Intervention and No Prior MI: Results From the VESALIUS-CV Trial.

This prespecified subgroup analysis of the VESALIUS-CV randomized trial evaluated evolocumab versus placebo in patients with prior percutaneous coronary intervention (PCI) but no prior myocardial infarction (MI), stratifying by PCI history. Over a median 4.6-year follow-up, the study assessed effects on coronary heart disease death/MI/ischemic stroke (3-point MACE) and the expanded composite including ischemia-driven revascularization (4-point MACE). The findings clarify whether intensive PC I–related secondary prevention with the PCSK9 inhibitor evolocumab provides incremental benefit in patients without prior MI.

Bergmark BA, Bohula EA, Marston NA et al. · Circulation · (2026) · View on PubMed ↗

SBK2-Driven NDUFV1 Phosphorylation and Translocation Limits Cardiac Hypertrophy.

This work investigated how the kinase SBK2 regulates mitochondrial complex I function and thereby limits pathological cardiac hypertrophy, using cross-species transcriptomic screening, UK Biobank analyses, and mechanistic cardiac studies. SBK2-driven phosphorylation and translocation of NDUFV1 constrained mitochondrial complex I activity in a way that reduced cardiac hypertrophy. The results identify an SBK2–NDUFV1 axis as a potential molecular lever for preventing or treating heart-failure–associated hypertrophy via mitochondrial regulation.

Sun Y, Wu Q, Lei F et al. · Circulation research · (2026) · View on PubMed ↗

Small-Molecule Oral Versus Injectable Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Comparative Efficacy, Safety, and Future Clinical Perspectives.

This narrative review compared oral versus injectable glucagon-like peptide-1 receptor agonists (GLP-1RAs) for type 2 diabetes and cardiometabolic outcomes, focusing on efficacy, safety, and future clinical directions. The key finding is that oral GLP-1RAs (including formulations using absorption enhancers such as oral semaglutide) have achieved clinically meaningful glycemic and weight benefits with safety profiles that are broadly comparable to injectable peptide agonists in appropriate populations. Clinically, it supports expanding oral GLP-1RA options to improve adherence and access while maintaining cardiovascular and metabolic benefits.

Patel D · Cureus · (2026) · View on PubMed ↗ · Free PDF ↗

Single-cell and spatial transcriptomics identify immune-stromal interactions in cardiac allograft vasculopathy.

This study analyzed human cardiac allograft vasculopathy (CAV) by integrating single-cell RNA sequencing and spatial transcriptomics of donor coronary arteries. The key finding was that the CAV neointimal microenvironment is organized by specific immune–stromal cellular interactions that can be mapped in situ, helping define disease-relevant cellular and molecular programs. This is significant because it provides a mechanistic cellular atlas that could guide targeted therapeutic development to prevent or reverse CAV progression after heart transplantation.

Owen MC, Li DY, Shin H et al. · Nature cardiovascular research · (2026) · 1 citations · View on PubMed ↗

The host immune response to Mycobacterium tuberculosis determining protection or disease progression.

This narrative review studied triglyceride-rich lipoproteins (TRLs), including remnant particles, as targets for cardiovascular risk reduction beyond standard control of LDL cholesterol, blood pressure, and glycaemia. The key finding was that hypertriglyceridemia and TRLs contribute to atherosclerotic cardiovascular disease through pro-inflammatory and pro-thrombotic mechanisms, supported by mechanistic studies, observational cohorts, and Mendelian randomization. Clinically, it supports targeting triglycerides/TRLs as an actionable strategy to reduce residual cardiovascular risk in patients with persistent hypertriglyceridemia.

Saraiva M, Branchett WJ, Rengarajan J et al. · Nature immunology · (2026) · View on PubMed ↗

A RANKL+/CXCR4+ B cell population accumulates in bone marrow and causes age-related osteoporosis in mice.

This study examined the cellular source and regulation of RANKL in bone marrow during aging by focusing on RANKL+/CXCR4+ B cells (RCBs) in aged wild-type mice and in mice with conditional TRAF3 deletion in mesenchymal progenitor cells (MPCs). RCB numbers increased in aged bone marrow and were elevated in adult mice lacking TRAF3 in MPCs, with TGFβ1-induced TRAF3 degradation in MPCs promoting NF-κB-mediated CXCL12 expression that supported RCB accumulation. The work links the TRAF3–CXCL12 axis to RANKL-producing B-cell expansion and age-related osteoporosis, suggesting a pathway for targeting bone loss.

Li J, Fan J, Yao Z et al. · Bone research · (2026) · View on PubMed ↗ · Free PDF ↗

From complexity to clarity: aging bone marrow niche in bone and blood regeneration and malignancy.

This article reviewed how the bone marrow niche (BMN) changes with aging and how those changes affect bone and blood regeneration as well as malignancy, integrating evidence from high-resolution imaging, single-cell and spatial transcriptomics, and in vivo lineage tracing. It concludes that aging causes progressive functional decline across both hematopoietic and stromal compartments, reshaping niche signals that govern hematopoietic stem cell maintenance and osteogenesis. The synthesis highlights specific modern experimental approaches and mechanistic themes that can guide interventions to preserve regenerative capacity and reduce age-associated hematologic and skeletal malignancies.

Roy N, Liu H, Horenberg AL et al. · Bone research · (2026) · View on PubMed ↗ · Free PDF ↗

Adiposity-based obesity classification and cardiometabolic and kidney outcomes: a longitudinal UK Biobank analysis.

This longitudinal UK Biobank analysis studied whether an adiposity-based obesity classification combining body fat percentage (BF%) and waist circumference (WC) predicts cardiometabolic outcomes (3P-MACE, type 2 diabetes) and kidney outcomes (chronic kidney disease) in 489,311 participants. Participants were stratified into five BF%-WC risk groups with increasingly adverse adiposity profiles, and the study assessed associations and concordance relative to BMI (with results reported in the full text). The findings are clinically significant because they test whether fat amount and distribution outperform BMI for risk prediction of cardiovascular and renal disease.

Gunnarsson S, Karlsson C, Prasad RB et al. · EBioMedicine · (2026) · View on PubMed ↗ · Free PDF ↗

---

Neuroinflammation, neurodegeneration, and brain clearance

MIF modulates impaired astrocyte distribution in schizophrenia cortical spheroids.

This study generated human cortical spheroids from induced pluripotent stem cells (iPSCs) derived from 14 schizophrenia patients and 14 healthy controls to examine astrocyte organization and neuroinflammatory signaling. It identified abnormal baseline astrocyte distribution in schizophrenia spheroids that was triggered by macrophage migration inhibitory factor (MIF), and treatment with the MIF antagonist ISO-1 attenuated the abnormal distribution. The work links MIF-driven neuroinflammation to astrocyte mislocalization and supports MIF pathway modulation as a mechanistic therapeutic target in schizophrenia.

Requena Osete J, Szabo A, Akkouh IA et al. · Brain : a journal of neurology · (2026) · View on PubMed ↗ · Free PDF ↗

Parkinson’s disease beyond the brain: erythrocyte α-synuclein transfer across the blood-brain barrier.

This study investigated whether peripheral α-synuclein contributes to Parkinson’s disease by focusing on erythrocyte α-synuclein transfer across the blood–brain barrier using human tissues and mouse models. Using bone marrow transplantation, the authors showed that bone marrow-derived erythrocytic α-synuclein distributes to peripheral organs and reaches the brain at detectable levels, supporting a peripheral reservoir role in neurodegeneration. The findings broaden Parkinson’s disease pathogenesis beyond the brain and suggest erythrocyte-associated α-synuclein as a potential target for interrupting disease propagation.

Yang Y, Liu Q, Zhou T et al. · Brain : a journal of neurology · (2026) · View on PubMed ↗ · Free PDF ↗

Prediabetes as a critical stage for risk of dementia and stroke: evidence from the UK Biobank and Mendelian Randomization.

This study used UK Biobank data and Mendelian randomization to test whether prediabetes is a critical stage for later dementia and stroke risk and to identify glycemic thresholds where risk emerges. The key finding is that neurological risks (dementia and stroke) increase in relation to glycemic status, with evidence supporting that risk begins during prediabetes rather than only after progression to type 2 diabetes. These results have preventive implications by targeting earlier glycemic intervention to reduce downstream brain and vascular outcomes.

Han S, Naderi E, Wang K et al. · European journal of preventive cardiology · (2026) · 1 citations · View on PubMed ↗ · Free PDF ↗

Elevated AD biomarkers do not explain cognitive performance in a community-recruited clinical trial cohort.

This study examined whether elevated Alzheimer’s disease (AD) biomarkers explain cognitive performance in real-world older adults by comparing two multicenter cohorts: the community-recruited U.S. POINTER Imaging substudy and a matched sample from ADNI. The key finding is that higher AD biomarker levels did not account for cognitive performance differences in the community-recruited trial cohort. This is scientifically significant because it challenges assumptions that biomarker elevations alone reliably predict cognition in broader, less-selected populations.

Landau SM, Liu P, Harrison TM et al. · Alzheimer’s & dementia : the journal of the Alzheimer’s Association · (2026) · 1 citations · View on PubMed ↗ · Free PDF ↗

How does type 2 diabetes modify the risk of Alzheimer’s disease?

This narrative review plus re-analysis of post-mortem brain tissue molecular data investigated how type 2 diabetes (T2D) modifies Alzheimer’s disease (AD) risk. The key finding is that converging evidence—including single-cell transcriptomic data—suggests peripheral lipid abnormalities and inflammation in T2D may drive central inflammatory processes that contribute to AD risk. This is significant because it points to inflammation/lipid pathways as mechanistic targets linking T2D to dementia.

Sutherland GT, Chen A, Nguyen-Hao HT et al. · Alzheimer’s & dementia : the journal of the Alzheimer’s Association · (2026) · View on PubMed ↗ · Free PDF ↗

Reconstructing cerebral lymphatic clearance: an emerging target in the Alzheimer’s disease therapeutic pipeline.

This review summarized the therapeutic concept of reconstructing cerebral lymphatic clearance to improve brain clearance in Alzheimer’s disease. The key finding is that impaired meningeal lymphatic and glymphatic function may promote amyloid-β and tau accumulation, and that approaches targeting aquaporin-4 or VEGF-C signaling, as well as non-invasive methods like photobiomodulation and focused ultrasound, are being explored to modestly enhance clearance. This is clinically significant because it frames lymphatic/glymphatic restoration as an emerging AD treatment pipeline beyond traditional amyloid/tau targeting.

Zhang J, Zhang J, Ding J et al. · Alzheimer’s & dementia : the journal of the Alzheimer’s Association · (2026) · View on PubMed ↗

Targeting triglycerides for cardiovascular risk reduction.

This study used CODEX-CNS, a multiplexed protein imaging technology with a custom analysis pipeline, to perform spatial proteomic profiling of human frontal cortex tissue from 8 Alzheimer’s disease (AD) patients and 8 healthy controls. The key finding was that microglial states depend on the local microenvironment, including identification of a border-associated macrophage-like microglial subset linked to aging. Scientifically, it provides a high-resolution map of microglial heterogeneity in human AD that could inform microenvironment-targeted interventions.

Maiorca C, Tramontano D, Di Costanzo A et al. · Internal and emergency medicine · (2026) · View on PubMed ↗ · Free PDF ↗

A comparative transcriptomic analysis of mouse demyelination models and multiple sclerosis lesions.

This study compared single-cell transcriptomic profiles from mouse demyelination models—cuprizone (CPZ) and lysophosphatidylcholine (LPC)—with human multiple sclerosis (MS) lesions by integrating newly generated and published datasets. CPZ induced a distinct stressed oligodendrocyte state marked by Cdkn1a and Nupr1 that resembled MS lesion phenotypes, while both models converged on an immune-responsive oligodendrocyte program expressing Socs3, B2m, and interferon-response genes. The cross-model and human alignment clarifies which oligodendrocyte injury states are shared versus model-specific, improving translational interpretation of demyelination experiments.

Aboelnour EL, Vanoverbeke VR, Maupin EA et al. · Nature communications · (2026) · 2 citations · View on PubMed ↗ · Free PDF ↗

---

Neuroscience circuits & neurobiology tools

A multi-agent system for automating scientific discovery.

This study tested Robin, a multi-agent AI system designed to automate multiple stages of experimental biology, including literature search, hypothesis generation, experiment proposal, and data analysis. Robin integrates literature-search agents with data-analysis agents to generate hypotheses, propose experiments, interpret results, and iteratively update hypotheses in a semi-autonomous discovery loop. The scientific significance is that it represents a step toward end-to-end automation of hypothesis–experiment–analysis cycles in biology.

Ghareeb AE, Chang B, Mitchener L et al. · Nature · (2026) · View on PubMed ↗

Accelerating scientific discovery with Co-Scientist.

This study introduced Co-Scientist, a multi-agent AI system built on Gemini that performs structured scientific thinking and hypothesis generation conditioned on research objectives and prior evidence. Co-Scientist generates demonstrably novel, testable hypotheses for experimental verification using agents that continuously generate, critique, and refine ideas with scaled test-time compute. Its significance lies in accelerating the early discovery phase by improving the novelty and rigor of hypothesis generation for experimental biology.

Gottweis J, Weng WH, Daryin A et al. · Nature · (2026) · View on PubMed ↗

Novelty exploration-activated ensemble in the lateral hypothalamus confers analgesic and anxiolytic effects.

This study examined whether a novelty exploration–activated neuronal ensemble in the lateral hypothalamus (LH) modulates pain and anxiety in mice. Using a Fos-driven viral strategy, the authors identified an LH ensemble activated by novelty exposure and pain/anxiety-like stimuli, where activation produced analgesic and anxiolytic effects and inhibition worsened pain and anxiety-like behaviors; the ensemble included both GABAergic and glutamatergic subpopulations. The findings define a specific LH circuit as a potential target for interventions that treat both pain and negative affect.

Jia T, Peng YT, Sun YL et al. · Nature communications · (2026) · View on PubMed ↗

A modular multi-color fluorescence microscope for simultaneous tracking of cellular activity and behavior.

This study developed a modular multi-color epifluorescence tracking microscope for simultaneous ratiometric imaging of cellular activity and behavior in moving animals. Built from commercial parts in about 3 hours, the system enabled calcium imaging in behaving Caenorhabditis elegans and dual-color fluorescence tracking of muscle dynamics in Drosophila melanogaster larvae. Scientifically, it provides an accessible imaging platform for linking genetically encoded activity reporters to behavior in vivo.

Ramahefarivo E, Böger L, Saichol T et al. · Nature communications · (2026) · View on PubMed ↗

Minute-scale control of ubiquitin-mediated degradation reveals dynamics of bacterial secreted effector-functions.

This study developed AIDE (Auxin-Inducible Degradation of Effectors) to enable minute-scale, reversible, spatially confined degradation of bacterial secreted effector proteins delivered into host cells. By integrating a minimal auxin-inducible degron (AID) tag into effector genes, AIDE harnessed the host ubiquitin-proteasome system to selectively eliminate effectors, including membrane-integrated ones, while preserving native expression. The platform provides a powerful tool to dissect the temporal dynamics of bacterial effector functions during infection and host-pathogen interactions.

Zhang H, Guo Y, Adhikari B et al. · Nature communications · (2026) · View on PubMed ↗ · Free PDF ↗

Systematic discovery of motif-based interactions of the auxiliary domains of USP family deubiquitinases.

This study systematically mapped how auxiliary domains (ADs) of USP family deubiquitinases (DUBs) mediate substrate targeting by testing motif-based interactions of 29 USP-ADs and two full-length USPs. It assessed whether ADs bind short linear motifs (SLiMs) in intrinsically disordered regions to regulate DUB activity and localization. The findings advance a mechanistic framework for USP substrate specificity beyond catalytic domains, informing how DUBs are targeted within cellular protein networks.

Konstantinou A, Córdova-Pérez A, Varga JK et al. · Nature communications · (2026) · View on PubMed ↗ · Free PDF ↗

Engineering yeast chromosomal telomeres with a bacteriophage system.

This study engineered the single-chromosome yeast Saccharomyces cerevisiae by replacing endogenous telomeres with the bacteriophage N15 prokaryotic TelN/tos telomere system, using disruption of the MRX/Sae2 pathway. The phage TelN/tos telomeres effectively protected linear chromosome ends and prevented genetic instability, with adaptive evolution further improving performance. This provides a phage-derived strategy to rewire eukaryotic chromosome-end maintenance and a platform to dissect telomere protection mechanisms across domains of life.

Deng W, Li Y, Shao Y et al. · Nature communications · (2026) · View on PubMed ↗ · Free PDF ↗

Diverse mechanisms of translation arrest by a Clostridia ribosome stalling peptide CliM.

This study investigated the translation arrest mechanism of the Clostridia ribosome stalling peptide CliM in relation to the YidC membrane insertase, using cryo-EM-based structural and mutational analyses in Clostridium kluyveri and Clostridioides difficile. CliM senses YidC activity and triggers different arrest outcomes—elongation arrest at multiple sense codons in C. kluyveri versus termination arrest in C. difficile—via distinct structural conformations of the nascent polypeptide exit region. These findings reveal how a bacterial arrest peptide couples ribosome stalling to membrane protein biogenesis capacity, informing general principles of programmed translational control.

Yoshida M, Gersteuer F, Berendes O et al. · Nature communications · (2026) · View on PubMed ↗ · Free PDF ↗

Decoding spatial transcriptomics across multicellular and subcellular resolutions.

This study developed STARS (Spatial Transcriptomics across Resolutions for Single Cells) to reconstruct transcriptomes across multicellular and subcellular spatial transcriptomics resolutions, integrating spot-level RNA data with high-resolution histology images. Using a Vision Transformer model and contrastive learning, STARS improved the decomposition/aggregation of spots to achieve single-cell-resolution transcriptome inference. This computational advance addresses a key limitation of current spatial transcriptomics platforms and enables more accurate single-cell spatial biology across resolution scales.

Zhao C, Liu T, Miller LM et al. · Nature communications · (2026) · View on PubMed ↗ · Free PDF ↗

Neuronal degeneration: Axons bend without breaking by controlling microtubule motion.

This Current Biology commentary summarized in vivo neuronal studies in Caenorhabditis elegans showing how neurons respond to body-motion–induced axonal forces by maintaining cytoskeletal continuity. The key finding is that talin and RhoA signaling drives microtubule oscillations via non-muscle myosin II, allowing axons to bend without breaking under mechanical stress. This is scientifically significant because it identifies a mechanotransduction pathway that could inform strategies to preserve axonal integrity in neurodegenerative or injury contexts.

Miller KE · Current biology : CB · (2026) · View on PubMed ↗

---

Epilepsy & ion channel pharmacology

Potassium channel agonists emerging as treatment options for focal epilepsy: are we breaking new ground?

This mini-review evaluated emerging focal-epilepsy therapies targeting Kv7 (KCNQ) potassium channels, focusing on the clinical development of Kv7 modulators and their mechanistic rationale as a “molecular brake” on neuronal firing. The key finding is that Kv7 modulation is progressing as a more precision-oriented approach than broad synaptic neurotransmission modulation, with the potential to improve tolerability and reduce dose-limiting adverse effects. Clinically, this supports Kv7 (KCNQ) channels as a high-priority drug target for next-generation antiseizure medications in patients with focal epilepsy.

Pelorosso C, Balestrini S, Guerrini R · Expert opinion on emerging drugs · (2026) · View on PubMed ↗

Role for TREK-1 as a polymodal sensor and regulator of cell activity.

This article reviewed and synthesized evidence on TREK-1 (KCNK2), a polymodal two-pore-domain potassium (K2P) channel, as both a sensor and regulator of cellular activity across tissues. The key finding is that TREK-1 integrates mechanical, chemical, and thermal inputs and also participates in noncanonical signaling roles through protein interactions, trafficking, and modulation of MAPK and calcineurin pathways. Scientifically, it positions TREK-1 as a mechanistic hub for translating environmental cues into changes in excitability and intracellular signaling, informing therapeutic strategies targeting KCNK2.

Winkle AJ, Odayil Muralidharan A, McClenney CR et al. · Channels (Austin, Tex.) · (2026) · View on PubMed ↗ · Free PDF ↗

---

Respiratory medicine (asthma/COPD/ILD/PE) & pulmonary therapeutics

Dupilumab in COPD: A Pooled Analysis of Emergency Department Visits, Hospital Admissions, and Systemic Corticosteroid Use.

This pooled analysis combined data from the BOREAS and NOTUS phase 3 randomized, double-blind, placebo-controlled trials to evaluate dupilumab’s effects during COPD exacerbations on emergency department visits, hospital admissions, and systemic corticosteroid use. The analysis assessed exacerbation-related healthcare utilization and cumulative corticosteroid exposure in patients receiving dupilumab versus placebo. These findings aim to determine whether targeting IL-4/IL-13 signaling with dupilumab reduces acute exacerbation instability and steroid burden in COPD.

Bhatt SP, Martinez FJ, Satia I et al. · American journal of respiratory and critical care medicine · (2026) · View on PubMed ↗

Single-cell Sequencing Unveils A Profibrotic Macrophage and Infiltrating Monocyte Niche in the Bronchoalveolar Lavage of Patients with Chronic Obstructive Pulmonary Disease.

This study used single-cell sequencing of bronchoalveolar lavage (BAL) immune cells to compare patients with chronic obstructive pulmonary disease (COPD) versus healthy controls and relate immune-cell composition to airflow limitation severity. COPD BAL contained a profibrotic macrophage and an infiltrating monocyte niche that were not seen (or were less prominent) in controls, linking these cell states to worse disease severity. These findings provide a human, cell-resolved immune map of COPD distal-airway inflammation that could guide targeted anti-fibrotic or immunomodulatory therapies.

Gerayeli FV, Yang CX, Wang CJ et al. · American journal of respiratory and critical care medicine · (2026) · View on PubMed ↗

Interstitial Lung Disease in Patients With Unresectable Stage III NSCLC Treated With Chemoradiotherapy Followed by Durvalumab in Japan: Analysis From the Multicenter Prospective AYAME Study.

This prospective multicenter analysis from the AYAME study evaluated long-term interstitial lung disease (ILD) outcomes in Japanese patients with unresectable stage III non-small cell lung cancer (NSCLC) treated with chemoradiotherapy followed by durvalumab. The key finding was that ILD incidence, severity, and management could be characterized over up to 3 years of follow-up, with patient factors assessed for association with ILD risk. Scientifically and clinically, it informs risk monitoring and management strategies for durvalumab-associated ILD in this specific post-CRT NSCLC population.

Yamamoto N, Kenmotsu H, Ninomiya K et al. · Thoracic cancer · (2026) · View on PubMed ↗ · Free PDF ↗

Safety, Pharmacokinetics, and Efficacy of 1.5% Ruxolitinib Gel (HDM3010) in Adult Patients with Prurigo Nodularis: A Phase I/II, Randomized, Double-Blind, Vehicle-Controlled Multicenter Clinical Trial.

This phase I/II randomized, double-blind, vehicle-controlled multicenter trial evaluated topical 1.5% ruxolitinib gel (HDM3010), a JAK inhibitor, in adult patients with prurigo nodularis (PN). The key finding was that HDM3010 showed an acceptable safety profile and demonstrated efficacy signals for reducing PN symptoms compared with vehicle during a 4-week double-blind period (with once-daily or twice-daily dosing arms). Clinically, this supports topical JAK inhibition as a potential targeted treatment option for chronic inflammatory PN with limited existing therapies.

Wu C, Niu X, Wang X et al. · Dermatology and therapy · (2026) · View on PubMed ↗ · Free PDF ↗

Efficacy and safety of tezepelumab versus placebo in reducing oral corticosteroid use in adults with severe, oral corticosteroid-dependent asthma (SUNRISE): a multicentre, placebo-controlled, double-blind, phase 3 trial.

In the SUNRISE phase 3 multicentre, placebo-controlled, double-blind trial, adults aged 18–80 years with severe, oral corticosteroid-dependent asthma received the anti–thymic stromal lymphopoietin monoclonal antibody tezepelumab 210 mg subcutaneously every 4 weeks versus placebo for 28 weeks after oral corticosteroid optimization. Tezepelumab significantly reduced oral corticosteroid use compared with placebo, demonstrating an oral corticosteroid–sparing effect. This is clinically important because it offers a mechanism-targeted biologic strategy to reduce systemic steroid exposure in a population at high risk from chronic oral corticosteroids.

Wechsler ME, Brightling CE, Brusselle G et al. · The Lancet. Respiratory medicine · (2026) · 1 citations · View on PubMed ↗ · Free PDF ↗

Safety and efficacy of astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): randomised, double-blind, placebo-controlled, phase 2b and 3 trials.

The ALIENTO (phase 2b) and ARNASA (phase 3) randomized, double-blind, placebo-controlled trials evaluated astegolimab, an anti–ST2 (IL-33 receptor) human IgG2 monoclonal antibody, in current/former smokers with COPD and frequent exacerbations regardless of baseline blood eosinophil counts. The key finding is the reported safety and efficacy of astegolimab across these two pivotal trials in an eosinophil-independent exacerbation population. This is significant because it tests whether targeting the IL-33/ST2 axis can reduce COPD exacerbations without relying on eosinophil stratification.

Papi A, Greening NJ, Bhatt SP et al. · Lancet (London, England) · (2026) · 1 citations · View on PubMed ↗

---

Infectious disease immunology & host-directed strategies

Meteorin-like ameliorates acute bacterial lung infection by enhancing neutrophil function.

This study measured Meteorin-like (METRNL) in animals and patients with bacterial pneumonia and used genetic and pharmacologic approaches to define its role in host defense. METRNL production was markedly suppressed during acute bacterial lung infection, and METRNL loss increased mortality and bacterial burden in models of Pseudomonas aeruginosa and Staphylococcus aureus pneumonia. The results indicate that METRNL enhances neutrophil function and may represent a therapeutic or biomarker target for acute bacterial lung infections.

Ding H, Liu J, Gong Y et al. · American journal of respiratory cell and molecular biology · (2026) · View on PubMed ↗

Spatial proteomic analysis in human Alzheimer’s disease brains enables identification of microenvironment-dependent microglial cell states.

This review studied how the host immune response to Mycobacterium tuberculosis determines whether infection is controlled or progresses to active tuberculosis (TB) disease. The key finding was that immune correlates of protection are insufficient to predict vaccine efficacy or individual outcomes across the spectrum of infection states, reflecting the complexity and heterogeneity of M. tuberculosis infection. This is significant because it motivates improved, state-aware immunological biomarkers and vaccine/host-directed strategies to better predict and prevent progression to active TB.

Sanchez-Molina P, Rosmus DD, Brownell D et al. · Nature neuroscience · (2026) · View on PubMed ↗ · Free PDF ↗

Phage-encoded factor stimulates DNA degradation by the Hna anti-phage defense system.

This study characterized the phage-encoded factor that modulates the Hna anti-phage defense system in bacteria using biochemistry, cryo-electron microscopy, and single-molecule fluorescence imaging. Hna was shown to function as a 3′–5′ single-stranded DNA exonuclease that forms an auto-inhibited dimer under physiological ATP, with catalytic output controlled by kinetic partitioning between ATPase and nuclease activities. Mechanistically defining how Hna degrades DNA during abortive infection advances understanding of bacterial immunity and phage countermeasures.

Hooper MM, Hoover BT, Zhang H et al. · Nature communications · (2026) · View on PubMed ↗

Vaccine-Induced Anti-HBs Response Is Associated with Protection Against Hepatitis B Virus Reactivation after Allogeneic Hematopoietic Cell Transplantation: A Randomized Trial.

This randomized trial evaluated whether hepatitis B (HepB) vaccination after allogeneic hematopoietic cell transplantation (allo-HCT) reduces hepatitis B virus (HBV) reactivation in patients with resolved HBV infection. The study tested the association between vaccine-induced anti-HBs antibody responses and protection against HBV reactivation after allo-HCT, alongside the trial’s preventive effect of vaccination. The results are significant because they provide prospective evidence for a strategy to prevent HBV reactivation beyond nucleos(t)ide analog preemption.

Onozawa M, Kusumoto S, Kuwatsuka Y et al. · Transplantation and cellular therapy · (2026) · View on PubMed ↗

---

Clinical trial methods, rehabilitation, and health outcomes

Real-world outcomes and early discontinuation of foslevodopa/foscarbidopa in Parkinson’s disease.

This real-world multicenter cohort followed consecutive Parkinson’s disease patients initiating continuous subcutaneous foslevodopa/foscarbidopa infusion (LDp/CDp) for 6 months, assessing MDS-UPDRS and PDQ-39 trajectories and early discontinuation. LDp/CDp improved or stabilized clinical outcomes over follow-up (analyzed with linear mixed-effects models with FDR correction), while treatment persistence and discontinuation risk were quantified using Kaplan–Meier and Cox proportional hazards models. The results provide practical evidence on multidomain effectiveness and early discontinuation patterns for this device-aided dopaminergic therapy in advanced PD.

Tsuboi T, Kimura K, Ikenaka K et al. · Journal of neurology · (2026) · View on PubMed ↗

Nationwide epidemiological survey of autoimmune pancreatitis in Japan in 2021.

This nationwide Japanese epidemiological survey (two-stage design) estimated the prevalence and incidence of autoimmune pancreatitis (AIP) in 2021 and characterized clinical features in treated patients. The study estimated 16,750 people with AIP in 2021 (prevalence 13.3 per 100,000) and 4,210 newly diagnosed cases (annual incidence 3.4 per 100,000), with detailed clinical data available for 2,833 patients. These updated population-level metrics refine the current burden of AIP in Japan and support planning for diagnosis and management strategies.

Masamune A, Sano T, Takikawa T et al. · Journal of gastroenterology · (2026) · View on PubMed ↗

The 1-year obesity treatment intervention can improve fasting plasma glucose in children aged 6-12 years: randomized controlled trial.

This randomized controlled trial studied a 1-year multidisciplinary lifestyle obesity intervention (pediatrician, nurse, clinical nutritionist; visits every 3 months; 5 sessions total) in Finnish children aged 6–12 years with overweight or obesity. The intervention improved fasting plasma glucose over 1 year (with effects on BMI-for-age, metabolic markers, and quality of life assessed). If confirmed in full results, this supports structured, low-burden pediatric obesity treatment as a strategy to improve early metabolic risk.

Martikainen A, Eloranta AM, Schwab U et al. · Trials · (2026) · View on PubMed ↗ · Free PDF ↗

Low-Dose Buprenorphine Following Ketamine Treatment for Suicidal Ideation in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial.

This randomized, double-blind, placebo-controlled trial studied low-dose sublingual buprenorphine (a partial mu-opioid receptor agonist) as follow-on treatment after intravenous ketamine in adults with major depressive disorder (MDD) and suicidal ideation. The trial tested whether buprenorphine could prolong ketamine’s antisuicidal effect while assessing safety and tolerability. If effective, this would be clinically significant as a strategy to extend ketamine’s benefits for suicide risk in MDD.

Tucciarone JM, Bandeira ID, Blasey C et al. · The American journal of psychiatry · (2026) · View on PubMed ↗

Associations of the Lifestyle for Brain Health (LIBRA) index with cognitive functioning across adulthood: Variation by sex and socioeconomic status in the German National Cohort (NAKO).

This population-based analysis in the German National Cohort (NAKO; n=149,948; ages 20–75) studied associations between the Lifestyle for Brain Health (LIBRA) index and cognitive functioning across adulthood, examining variation by sex and socioeconomic status. The key finding (as framed in the abstract) is that LIBRA factor frequencies and their relationships with cognition differ by demographic strata, with behavioral/psychosocial risks (e.g., smoking and physical inactivity) contributing to cognitive associations. These results are significant for targeting modifiable dementia risk factors using an index-based approach tailored to sex and socioeconomic context.

Röhr S, Wittmann F, Luppa M et al. · Alzheimer’s & dementia : the journal of the Alzheimer’s Association · (2026) · View on PubMed ↗

Guideline-based prognostic factors associated with mortality in pulmonary embolism: a systematic review and meta-analysis.

This systematic review and meta-analysis studied prognostic clinical variables associated with short-term mortality in adult inpatients with confirmed acute pulmonary embolism (PE) by searching Medline and EMBASE through 19 May 2025. It aimed to quantify the adjusted odds ratios linking guideline-based predictors to mortality, using only adjusted OR from included studies. The results are intended to improve risk stratification for acute PE by identifying which routinely assessed factors best predict early death.

Durr K, Rochwerg B, Fernando SM et al. · Thorax · (2026) · View on PubMed ↗

European Society of Cardiology: cardiovascular disease statistics 2025.

This European Society of Cardiology (ESC) Atlas report analyzed cardiovascular disease statistics for 2025, comparing more than 50 ESC member countries using the latest available data for 2024 or similar years. It stratified outcomes by sex and World Bank national income status to quantify inequalities in CVD risk, management, and outcomes across countries. The report is significant for informing EU-level policy initiatives (including the “Safe Hearts Plan”) aimed at reducing the cardiovascular burden.

Timmis A, Petersen SE, Van Belle E et al. · European heart journal · (2026) · View on PubMed ↗

Deconstructing White Dot Syndromes - Multimodal Imaging in Uveitis (MUV) Taskforce: Report 11.

This perspective review examined whether the clinical construct of “white dot syndromes” (WDS) remains valid for non-infectious posterior uveitis (NIPU) in the era of advanced retinal and choroidal imaging, drawing on literature and observations using structural high-resolution OCT and OCT angiography. The authors argue that the umbrella WDS terminology may obscure distinct underlying pathophysiology and that multimodal imaging can better deconstruct and differentiate entities previously grouped by fundus “white dots.” This reframing is clinically significant because it supports more precise diagnosis and potentially more tailored management of posterior uveitis phenotypes rather than relying on a historical funduscopic label.

Invernizzi A, Agarwal A, Jampol LM et al. · American journal of ophthalmology · (2026) · View on PubMed ↗ · Free PDF ↗

The International Agency for Research on Cancer: from global evidence to national action.

This article reviewed the International Agency for Research on Cancer (IARC) contribution to translating global cancer evidence into national policy and action, using insights from the IARC Impact in Practice series and country reports. The key finding is that the main barrier is shifting from generating evidence to understanding why evidence is adopted into policy and practice more effectively in some settings than others. This is significant for cancer control because it informs how evidence-to-action mechanisms can be strengthened in countries with limited capacity.

Schmütz A, Chajàs V, Chauvet C et al. · The Lancet. Public health · (2026) · View on PubMed ↗ · Free PDF ↗

Remote Multicomponent Rehabilitation in Intensive Care Unit Survivors: A Randomized Clinical Trial.

This JAMA randomized clinical trial evaluated a 6-week remote multicomponent rehabilitation program versus standard care in adult ICU survivors discharged within the prior 12 weeks across 52 UK National Health Service hospitals. The primary outcome was health-related quality of life at 8 weeks, with the intervention delivered remotely and assessed by blinded evaluators. The study is significant because it tests whether scalable, remote rehabilitation can improve post-ICU recovery outcomes in a broad real-world survivor population.

O’Neill B, Bradley JM, Connolly B et al. · JAMA · (2026) · View on PubMed ↗

---

---

Generated automatically on May 20, 2026 from PubMed’s trending articles. Summaries are AI-generated; always consult the original publication for clinical or research decisions.